MDGL Stock Madrigal Pharmaceuticals Inc - Complete Overview

Nasdaq / Pharmaceutical Products / Healthcare / MDGL Stock

Madrigal Pharmaceuticals Inc (MDGL) price per share as of 22 Jun 2018
USD
Your sentiment
COLDTRENDOMETERHOT
Shares Outstanding 14.25M
Avg Daily Volume 399.16K
Market Cap 1.66B
Volatility 68.36% HIGH

MADRIGAL PHARMACEUTICALS INC (MDGL) OVERVIEW

MDGL stock is a pharmaceutical products company traded on Nasdaq. It is valued at 1.66B US dollars. There are 14.25M shares outstanding which Madrigal Pharmaceuticals Inc issued to investors. Volatility of the stock is HIGH, and the daily volume is 68.36% stock on average. It brought investors a total return of 1,842.96% over the last 12 months. Madrigal Pharmaceuticals Inc stock is relatively cheap. It's P/E ratio is below the market average.

Madrigal Pharmaceuticals Inc (MDGL) STOCK PRICE PERFORMANCE

MDGL SHAREHOLDER'S RETURN

Earnings Per Share 0.00
Dividends Per Share 0.00
12 Months Price Performance High
Total Return High

MDGL LATEST NEWS

Are These Red-Hot NASH Stocks Still a Buy?

Investors are piling into NASH stocks right now, but which ones are the best long-term buys?

Viking Therapeutics: What Now After 'Yuge' Rally?

In today's 'deep dive' we revisit an emerging developmental concern named Viking Therapeutics.The stock has nearly quadrupled over the past nine months, is there still more potential upside ahead?We t

3 Biotech Stocks That Soared This Week: Are They Buys?

Can these three sizzling-hot biotech stocks keep the momentum going?

Viking Therapeutics: Sell The Pop On The Sympathy Play

VKTX rose as a sympathy play to MDGL as investors surmise that the good data on MGL-3196 increases the probability of success for VK2089.VKTX has had substantial dilution of more than 100% over the la

Rounds Report: Madrigal Rallied, While Iterum Experienced Significant Insider Purchases

The overall bioscience market traded with a mixed sentiment for the day. Many equities under our coverage continued to procure increasing profits for shareholders.Madrigal Pharmaceuticals topped our f

Viking Therapeutics Doubles On Madrigal's Phase 2 NASH Data, What Comes Next?

Viking Therapeutics doubles on Madrigal's positive phase 2 NASH results. Viking expects to release its phase 2 NASH data for VK2809 by the second half of 2018, which could potentially drive the stock

Madrigal Pharmaceuticals Inc (MDGL) TECHNICAL INDICATORS

Name Value Action
RSI(14) 65.74 Strong buy
CMO(14) 31.49 Strong buy
ADX(14) 45.53 N/A
Williams %R -58.88 Overbought

MDGL FORUM DISCUSSIONS